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PROOF OF IMMUNOSURVEILLANCE
AND THE IMMUNOEDITING CONCEPT
The beginning of the second millennium
marked a turning point for tumor immu-
nity, on the basis of a series of data obtained
in mice and in humans. The enhanced
susceptibility of immunodeficient mice to
the formation of chemically induced or
spontaneous tumors clearly showed that
the immune system can eliminate nascent
tumors (1). A few years later, the investiga-
tions showing that high densities of T cells,
particularly with a Th1 and cytotoxic polar-
ization, in different locations of a primary
tumor, correlate with favorable prognosis
for disease-free and overall survival in large
series of cancer patients also strongly sup-
ported the fact that a natural immune reac-
tion controls invasion and metastasis (2).
Most importantly, these results also proved
the establishment of a long-term memory
against cancers and suggested that it could
be reactivated with tumor vaccines. Such
breakthroughs had major consequences for
the tumor immunity field. They paved the
way for a new era for tumor immunology,
building on solid foundations, and leaving
behind more than 50 years of errances since
the concept of tumor immunosurveillance
had been put forward. However, tumors
develop, invade tissues locally, metastasize
in distant organs, and ultimately cancer
can be life threatening. During these last
10 years, we also learnt that the immune
system “sculpts” tumors, leading to the
formation of tumor variants that escape
immunosurveillance, and/or inducing sup-
pressive conditions that facilitate tumor
outgrowth. Thus, cancer immunother-
apy should aim at boosting anti-tumor
immunity by breaking immune tolerance
or using adoptively transferred expanded
tumor infiltrating lymphocytes (already
present in the tumor). This last approach
has yielded promising results in terminally
ill cancer patients.
DEEPER IN THE TUMOR
MICROENVIRONMENT
In parallel and complementary to these
studies, it became evident that a tumor is
not only an aggregate of cancer cells but
also a complex organization that includes
blood and lymphatic vessels, stromal cells,
and cells of the immune system. Blood ves-
sels carry fluid, oxygen, nutriments, and
cells to tumors, and also drive tumor
growth through their interaction with the
extracellular matrix, and facilitate the for-
mation of niches of tumor stem cells.
An accumulating series of evidence sug-
gest that high endothelial venules (HEV),
mostly localized at the invasive margin of
tumors, allow the entry of lymphocytes
into tumors. The latter point is reinforced
by the fact that HEV are the only blood
vessels associated with a favorable clinical
outcome of cancer patients. Lymphocytes
can be primed by mature dendritic cells
(DC) locally, and then proliferate and dif-
ferentiate, forming peritumoral lymphoid
aggregates. These so-called tertiary lym-
phoid structures (TLS) (3) share many
features with secondary lymphoid organs.
Such a cellular organization most likely
facilitates the generation and maintenance
of local anti-tumor immune responses,
protected from the suppressive influences
of the tumor milieu. The lymphatic ves-
sels maintain fluid balance and trans-
port soluble and/or cell bound antigens.
They are known to play a detrimental
role in cancer since they participate to
the transport of metastazing tumor cells.
However, lymphatic vessels may also con-
tribute to cancer defenses since they allow
the exit of activated DC and memory
cells (generated in TLS) from the tumor.
Their potential diversity still has to be
explored.
The distribution and functions of
immune cell within tumors have been the
subject of intense studies. The immune
landscape contains distinct infiltrating
immune cell types with distinct densi-
ties, prognostic, and predictive significance
in tumors (4). Whereas mature DC, M1
macrophages, Th1 CD4+ T cells, and cyto-
toxic CD8+ T cells tend to reduce cancer
growth in the vast majority of cancers, M2
macrophages, myeloid-derived suppressor
cells (MDSC), and neutrophils exert an
opposite effect. The Th2 CD4+ T cells,
Th17 CD4+ T cells, Foxp3+CD4+ regu-
latory T (Treg) cells can play a pro or
anti-tumoral role, depending on the tumor
microenvironment. Moreover, beyond its
composition, the intra- and peritumoral
distribution, the architecture and the func-
tional organization of the immune infil-
trate – the immune contexture – play an






A large body of evidence came from
mouse and human studies showing that
T cells express multiple inhibitory mole-
cules that dampen their effector functions
upon recognition of their ligands. Anti-
bodies that block these interactions were
administrated to cancer patients. Several
recent studies based on randomized pro-
tocols demonstrate their impressive clinical
activity in subsets of patients in several can-
cer types, with little side effects for some of
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these agents, further illustrating the power
of the immune defenses against cancer (5).
BIG DATA, NEW AVENUES
In parallel to these seminal studies, the
last 10 years have witnessed the develop-
ment of collections of large public can-
cer data sets, including those of The Can-
cer Genome Atlas (TCGA), which provides
a comprehensive collection of aberrations
in the DNA, chromatin, and RNA of the
genomes of thousands of tumors relative
to matched normal cellular genomes in
20 different types of human cancers. This
unprecedented effort together with the
development of whole genome sequenc-
ing set the stage for important new data
and new analyses regarding many aspects
of tumor biology. The characterization
of the molecular heterogeneity of tumors
leading to the identification of subgroups
of patients with distinct survival rates
and responses to treatments – including
immunotherapies in the near future – set
the premises of personalized medicine.
Most importantly, the exome sequencing
strategies combined to a set of different
approaches including T cell epitope predic-
tion now allow the identification, in a rela-
tively short period of time, of the mutated
tumor antigens that are recognized by the
patient’s immune system (5). Hence, for
the first time it is possible to exploit these
strategies for an «à la carte»vaccination of
patients.
WHAT WILL COME NEXT?
Commensal microorganisms colonize bar-
rier surfaces. In addition to their role
in nutrient degradation, they modulate
innate and adaptive immunity. Their regu-
latory role on innate and adaptive immune
responses to tumors, and its consequences
on cancer progression and treatment are
beginning to be deciphered. Silent retro-
viruses hosted in lymphocytes can be reac-
tivated and help them to launch a rapid
response against pathogens through NFκB
activation. Their role in shaping immune
responses including those against cancer
may be uncovered in the coming years.
Indeed, metabolic pathways regulate
immune cell functions. Epidemiological
studies have shown links between patient’s
metabolism, diet consumption, and cancer
incidence. Moreover, there is growing evi-
dence that the dietary sensitive epigenetic
changes such as DNA methylation and
histone modifications, microRNAs expres-
sion can influence cancer development and
T cell function. How all these parame-
ters influence the tumor microenviron-
ment and the complex cross-talk between
tumor immunity and tumor metabolism
are questions that may be addressed in the
near future.
Dramatic progresses have been made
in the field of tumor immunology dur-
ing the preceding 15 years. Such advances
are being successfully translated to clinics.
However, in most cases, only subgroups
of patients respond to immunotherapies.
Microenvironment-based biomarkers have
been identified but their selection and
transfer to the bed side are still needed.
There is now no doubt that the immune
system can be a powerful ally against can-
cer. The developments in immune inter-
vention strategies are growing rapidly and
further progresses are not far away, that
will be crucial in cancer treatment for the
benefits of the patients.
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